Key result
Low to moderate doses of anthracyclines for childhood ALL were associated with progressive cardiac dysfunction, including diastolic dilation and decreased ejection fraction.
Why the study?
Does childhood treatment with low to moderate doses of anthracyclines (<300 mg/m2) cause late signs of cardiomyopathy in acute lymphoblastic leukemia survivors?
Cohort (n=63)
Does childhood treatment with low to moderate doses of anthracyclines (<300 mg/m2) cause late signs of cardiomyopathy in acute lymphoblastic leukemia survivors?
Answers are grounded in this paper and cite their sources.
Even low to moderate cumulative doses of anthracyclines (<300 mg/m2) in childhood ALL survivors can lead to progressive cardiac dysfunction, underscoring the need for lifelong echocardiographic surveillance.
BACKGROUND: At present about 80% of children with acute lymphoblastic leukemia (ALL) will be cured following treatment with multi-drug chemotherapy. A major concern for this growing number of survivors is the risk of late effects of treatment. The aim of this study was to determine whether signs of cardiomyopathy were present in patients treated in childhood with cumulative anthracycline doses of less than 300 mg/m(2). PROCEDURE: Evaluation of cardiac function in a cohort of 63 long-term survivors in first continuous remission following treatment of ALL with multi-drug chemotherapy including anthracyclines was performed using standard M-mode echocardiography and tissue doppler imaging (TDI). Associations between age at diagnosis, cumulative dose of anthracycline, sex, length of follow-up, and deviations from normal values in M-mode echocardiograms were evaluated using univariate and multivariate regression analysis. TDI data were compared to normal values using Wilcoxon matched-pairs signed-ranks test. RESULTS: By standard M-mode echocardiography the most significant findings were diastolic dilation of the left ventricle, thinner interventricular septum (IVS), decreased left ventricular mass (LVM) in females, follow-up dependent dilation of the left ventricle in systole and follow-up dependent decrease in ejection fraction (EF). TDI abnormalities included signs of early diastolic dysfunction and myocardial hypertrophy, and were also found in structures that appeared normal by M-mode echocardiography. CONCLUSIONS: This study adds to the growing evidence that even low to moderate doses of anthracyclines might lead to progressive cardiac dysfunction. It is important that children treated with anthracyclines receive life long follow-up for signs of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Rathe et al. (2007) conducted a cohort in Childhood acute lymphoblastic leukemia (n=63). Anthracycline containing therapy vs. Normal values was evaluated on Cardiac function evaluated by M-mode echocardiography and tissue doppler imaging. Low to moderate doses of anthracyclines for childhood ALL were associated with progressive cardiac dysfunction, including diastolic dilation and decreased ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: